State Street’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $80.7K | Hold |
133,333
| – | – | ﹤0.01% | 4065 |
|
|
2025
Q4 | $103K | Hold |
133,333
| – | – | ﹤0.01% | 4041 |
|
|
2025
Q3 | $135K | Hold |
133,333
| – | – | ﹤0.01% | 3997 |
|
|
2025
Q2 | $177K | Hold |
133,333
| – | – | ﹤0.01% | 3861 |
|
|
2025
Q1 | $159K | Hold |
133,333
| – | – | ﹤0.01% | 3877 |
|
|
2024
Q4 | $217K | Buy |
133,333
+21,500
| +19% | +$56.9K | ﹤0.01% | 3832 |
|
|
2024
Q3 | $427K | Sell |
111,833
-18,700
| -14% | -$62.4K | ﹤0.01% | 3624 |
|
|
2024
Q2 | $382K | Sell |
130,533
-426,787
| -77% | -$1.37M | ﹤0.01% | 3621 |
|
|
2024
Q1 | $2.21M | Buy |
557,320
+5,288
| +1% | +$27.2K | ﹤0.01% | 3247 |
|
|
2023
Q4 | $2.74M | Buy |
552,032
+47,091
| +9% | +$234K | ﹤0.01% | 3203 |
|
|
2023
Q3 | $2.55M | Buy |
504,941
+47,966
| +10% | +$263K | ﹤0.01% | 3227 |
|
|
2023
Q2 | $2.3M | Buy |
456,975
+354,442
| +346% | +$2.32M | ﹤0.01% | 3349 |
|
|
2023
Q1 | $631K | Buy |
102,533
+7,500
| +8% | +$61.4K | ﹤0.01% | 3666 |
|
|
2022
Q4 | $1.25M | Buy |
95,033
+13,800
| +17% | +$97.4K | ﹤0.01% | 3509 |
|
|
2022
Q3 | $241K | Hold |
81,233
| – | – | ﹤0.01% | 4053 |
|
|
2022
Q2 | $297K | Buy |
81,233
+4,700
| +6% | +$22.3K | ﹤0.01% | 4033 |
|
|
2022
Q1 | $474K | Buy |
76,533
+4,057
| +6% | +$25.2K | ﹤0.01% | 4069 |
|
|
2021
Q4 | $587K | Buy |
72,476
+9,500
| +15% | +$102K | ﹤0.01% | 3960 |
|
|
2021
Q3 | $938K | Buy |
62,976
+3,800
| +6% | +$47.4K | ﹤0.01% | 3795 |
|
|
2021
Q2 | $743K | Buy |
+59,176
| New | +$462K | ﹤0.01% | 3723 |
|
|
2019
Q1 | – | Sell |
-676
| Closed | -$4K | – | 3753 |
|
|
2018
Q4 | $4K | Hold |
676
| – | – | ﹤0.01% | 3754 |
|
|
2018
Q3 | $10K | Sell |
676
-106
| -14% | -$1.91K | ﹤0.01% | 3757 |
|
|
2018
Q2 | $17K | Sell |
782
-16,582
| -95% | -$346K | ﹤0.01% | 3743 |
|
|
2018
Q1 | $409K | Buy |
17,364
+2,436
| +16% | +$655K | ﹤0.01% | 3462 |
|
|
2017
Q4 | $2.8M | Buy |
14,928
+821
| +6% | +$165K | ﹤0.01% | 3059 |
|
|
2017
Q3 | $3.03M | Buy |
14,107
+239
| +2% | +$49.4K | ﹤0.01% | 3028 |
|
|
2017
Q2 | $2.85M | Buy |
13,868
+1,946
| +16% | +$383K | ﹤0.01% | 2991 |
|
|
2017
Q1 | $2.17M | Buy |
11,922
+1,907
| +19% | +$378K | ﹤0.01% | 3057 |
|
|
2016
Q4 | $2.5M | Buy |
10,015
+543
| +6% | +$123K | ﹤0.01% | 3015 |
|
|
2016
Q3 | $1.97M | Buy |
9,472
+1,562
| +20% | +$309K | ﹤0.01% | 2970 |
|
|
2016
Q2 | $1.6M | Buy |
7,910
+3,014
| +62% | +$533K | ﹤0.01% | 3112 |
|
|
2016
Q1 | $897K | Buy |
4,896
+1,535
| +46% | +$274K | ﹤0.01% | 3242 |
|
|
2015
Q4 | $841K | Buy |
+3,361
| New | +$1.08M | ﹤0.01% | 3246 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
State Street's PDSB Position: Q1 2026 in Review
State Street held its PDS Biotechnology (PDSB) position steady in Q1 2026 at 133,333 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4065.
State Street first reported a position in PDSB in Q4 2015 and has held it in 33 quarters since. The position peaked at $3.03M in Q3 2017. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- State Street held 133,333 shares of PDS Biotechnology worth $80.7K as of Q1 2026.
- State Street left its PDS Biotechnology share count unchanged in Q1 2026.
- PDS Biotechnology made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4065 holding.
- State Street first reported a position in PDS Biotechnology in Q4 2015 and has held it in 33 quarters since.
- State Street's PDS Biotechnology position peaked at $3.03M in Q3 2017.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.